Asymmetric dimethylarginine determines the effect of simvastatin on endothelium-dependent vasodilation in severe hypercholesterolemia

Bibliography

• Böger RH: Association of asymmetric dimethylarginine and endothelial dysfunction. Clin.Chem.Lab.Med.41, 1467–1472 (2003).
   Google Scholar
• Ardigo D, Stuehlinger M, Franzini L etal.: ADMA is independently related to flow­ mediated vasodilation in subjects at low cardiovascular risk. Eur.J.Clin.Invest. 37, 263–269 (2007).
   Google Scholar
• Vladimirova­Kitova LG, Deneva T, Angelova E, Nikolov F, Marinov B, Mateva N: Relationship of asymmetric dimethylarginine with flow­mediated dilation in subjects with newly detected severe hypercholesterolemia. Clin.Physiol. Funct.Imaging 28, 417–425 (2008).
   Google Scholar
• Pohl U, Holtz J, Busse R, Bassenge E: Crucial role of the endothelium in the vasodilator response to flow invivo. Hypertension 8, 37–44 (1985).
   Google Scholar
• Achan V, Ho HK, Heeschen C etal.:ADMA regulates angiogenesis: genetic and metabolic evidence. Vasc.Med. 10, 7–14 (2005).
   Google Scholar
• Jang, JJ, Ho HKV, Kwan HH, Fajardo LF, Cooke JP: Angiogenesis is impaired by hypercholesterolemia. Role of asymmetric dimethylarginine. Circulation 102, 1414–1419 (2000).
   Google Scholar
• Yu X, Li Y, Xiong Y: Increase of an endogenous inhibitor of nitric oxide synthesis in serum of high cholesterol fed rabbits. LifeSci. 54, 753–758 (1994).
   Google Scholar
• Böger RH, Bode­Böger SM, Szuba A etal.: Asymmetric dimethylagrinine (ADMA): a novel risk factor for endothelial dysfunction. It’s role in hypercholesterolemia. Circulation 98, 1842–1847 (1998). Elevation of asymmetric dimethylarginine (ADMA) is associated with impaired endothelium-dependent vasodilation. This abnormality is reversed by administration of l-arginine.
   Google Scholar
• Laufs U, La F, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97, 1129–1135 (1998).
   Google Scholar
• Jiang J, Jiang D, Tang Y, Li N, Deng H, Li Y: Effect of simvastatin on endothelium­ dependent vasorelaxation and endogenous nitric oxide synthase inhibitor. ActaPharmacol.Sin.25, 893–901 (2004). Demonstrates that the protective effect of simvastatin on endothelial cells might be due to reduction of inflammatory reaction, but not alternation of ADMA level.
   Google Scholar
• Päivä H, Laakso J, Lehtimäki T, Isomustajärvi M, Ruoko I, Laaksonen R: Effect of high­dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J.Cardiovasc.Pharmacol. 41, 219–222 (2003).
   Google Scholar
• Santili F, Bucciarelli L, Noto D etal.: Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. FreeRadic.Biol.Med. 43, 1255–1262 (2007).
   Google Scholar
• Periera EC, Bertolami MC, Faludi AA, Salem M, Bersch D, Abdalla D: Effects of simvastatin and l­arginine on vasodilation, nitric oxide metabolites and endogenous NOS inhibitors in hypercholesterolemic subjects. FreeRadic.Res. 37, 529–536 (2003). Simvastatin reduced the plasma concentrations of nitric oxide (NO) metabolites without affecting either the levels of ADMA or endothelium-dependent vasodilation in hypercholesterolemia.
   Google Scholar
• Lu TM, Ding YA, Leu HB: Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am.J.Cardiol. 94, 157–161 (2004).
   Google Scholar
• Beckman JA, Liao JK, Hurley S etal.: Atorvastatin restores endothelial function in normocholetserolemic smokers independent of changes in low density lipoprotein. Circ.Res. 95, 217–223 (2004).
   Google Scholar
• Jörvisalo MJ, Toikka JO, Vasankari T etal.: HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis 147, 237–242 (1999).
   Google Scholar
• Simons LA, Sullivan D, Simons J, Celermajer DS: Effects of atorvastatin monotherapy and simvastatin plus cholesteramine on arterial endothelial function in patients with severe primary hypercholesterolemia. Atherosclerosis 137, 197–203 (1998).
   Google Scholar
• Vogel RA, Correti MC, Plotnick GD: Changes in flow­mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle­aged men. Am. J.Cardiol.77, 37–40 (1996).
   Google Scholar
• van Haelst PL, van Doormaal JJ, Asselbergs FW etal.:Correlates of endothelial function and their relationship with inflammation in patients with familial hypercholesterolemia. Clin.Sci. 104, 627–632 (2003). Aggressive lipid-lowering therapy with simvastatin does not result in improved endothelial function or in a reduction of markers of inflammation in these patients.
   Google Scholar
• Sheu WH, Juang BL, Chen YT, Lee WJ: Endothelial dysfunction is not reversed by simvastatin treatment in Type 2 diabetes patients with hypercholesterolemia. Diabetes Care 22, 1224–1225 (1999).
   Google Scholar
• Van Venrooij FV, Van de Ree MA, Bots ML, Stolk RP, Huisman MV, Banga JD: Aggressive lipid lowering does not improve endothelial function in Type 2 diabetes. DiabetesCare 25, 1211–1216 (2002). Aggressive lipid-lowering therapy with simvastatin does not result in improved endothelial function or in a reduction of markers of inflammation in these patients.
   Google Scholar
• Jongh S, Lilien MR, Roods J, Stroes E, Bakker HD, Kastelein J: Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J.Am.Coll. Cardiol.40, 2117–2121 (2002). Data demonstrating significant improvement of endothelial dysfunction towards normal levels after short-term simvastatin therapy in children with familial hypercholesterolemia.
   Google Scholar
• Janatuinen T, Laakso J, Laaksonen R etal.: Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults. Vasc.Med. 8, 185–189 (2003). Low baseline plasma ADMA concentration (< median) predicted a significant improvement of adenosine-induced blood flow after statin intervention, whereas high baseline ADMA (≥ median) was associated with no increase in adenosine-induced flow.
   Google Scholar
• Böger GI, Rudolf TK, Renke M etal.: Asymmetric dimethylarginine determines the improvement of endothelium­dependent vasodilatation by simvastatin.J.Am.Coll. Cardiol. 49, 2274–2282 (2007). Simvastatin does not enhance endothelial function in subjects with elevated ADMA, whereas it does in patients with low ADMA. Combination of simvastatin with oral l-arginine improves endothelial function in subjects with high ADMA, but has no additional effect in subjects with low ADMA.
   Google Scholar
• Scientific Steering Committee on behalf of the Simon Broome Register Group: Mortality in treated heterozygous familial hypercholesterolemia: implications for clinical management. Atherosclerosis 142, 105–112 (1999).
   Google Scholar
• Celermajer DS, Sorensen KE, Gooch VM etal.: Non­invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet340, 1111–1115 (1992).
   Google Scholar
• Mehta JL: Statins:UnderstandingClinicalUse. Saunders, PA, USA (2004).
   Google Scholar
• Jiang J, Jiang D, Tang Y, Li N, Deng H, Li Y: Effect of simvastatin on endothelium­ dependent vasorelaxation and endogenous nitric oxide synthase inhibitor. Acta Pharmacol.Sin.25, 893–901 (2004). Demonstrates that the beneficial effects of simvastatin on the vascular endothelium may be related to the reduction of inflammatory cytokine TNF-a, but it has no effect on the concentration of ADMA.
   Google Scholar
• Kielstein JT, Donnerstag F, Gasper S etal.: ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 37, 2024–2029 (2006). Results of this study document for the first time that suppressor doses of ADMA increase vascular stiffness and decrease cerebral perfusion in healthy subjects.
   Google Scholar
• Bates K, Ruggeroli CE, Goldman S, Gaballa MA: Simvastatin restores endothelial NO mediated vasorelaxation in large arteries after myocardial infarction. Am.J.Physiol. 283, H768–H775 (2002).
   Google Scholar
• Wilson SH, Simari RD, Best PJ etal.: Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler. Thromb.Vasc.Biol.21, 122–128 (2001).
   Google Scholar
• Guven GS, Atalar E, Yavuz B etal.: Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholesterolemia. J.Natl Med.Assoc.98, 627–630 (2006).
   Google Scholar
• Böger RH: Asymmetric dimethylarginine (ADMA) modulates endothelial function – therapeutic implications. Vasc.Med. 8, 149–151 (2003). Suggests that statins should resume their effect in patients with a high ADMA concentration when statins are administered in combination with l-arginine. Excess l-arginine would competitively displace ADMA from the NO synthase (NOS), thereby reducing its inhibitory effect, and restoring NOS activity.
   Google Scholar
• Böger RH, Sydow K, Borlak J etal.: LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells. Circ.Res.87, 99–105 (2000).
   Google Scholar
• Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP: Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99, 3092–3095 (1999).
   Google Scholar
• Miltiadous G, Papakostas J: Letter to the Editor: statins and homocysteine. Atherosclerosis166, 199–200 (2003).
   Google Scholar
• Lüftjohann D, Sigit JI, Locatelli S, Bergmann K: Letter to the Editor: high­dose simvastatin (80 mg/day) decreases plasma concentrations of total homocyst(e)ine in patients with hypercholesterolemia. Atherosclerosis155, 265–266 (2001).
   Google Scholar
• Sardo MA, Castado M, Cinquegrani M etal.: Effects of simvastatin treatment on sICAM­1 and sE­selectin levels in hypercholesterolemic subjects. Atherosclerosis 155(1), 143–147 (2001).
   Google Scholar
• Vladimirova­Kitova LG, Deneva TI, Angelova E, Bichev AN, Nikolov FP: Role of some biomarkers of atherogenic risk in the screening for molecular defects in the low density lipoprotein receptor in severe hypercholesterolemia. FoliaMed. 50(3), 14–22 (2008).
   Google Scholar
• Tamai O, Matsuoka H, Itabe H etal.: Single LDL apheresis improves endothelium­ dependent vasodilatation in hypercholesterolemic humans. Circulation 95(1), 76–82 (1997).
   Google Scholar
• Vlachopoulos C, Aznaouridis K, Dagre A etal.: Protective effect of atorvastatin on acute systemic inflammation­induced endothelial dysfunction in hypercholesterolaemic subjects. Eur.HeartJ. 28, 2102–2109 (2007).
   Google Scholar
• Landmesser U, Hornig B, Drexler H: Endothelial dysfunction in hypercholesterolemia – mechanisms, pathophysiological importance and therapeutic interventions. Semin.Thromb. Hemost.26, 529–537 (2000).
   Google Scholar